Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q2 2022 call → NOWe need to determine if management conveys that outsiders are currently underweighting something the company has already done, and if they point to a concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of reported results. Let's analyze the transcript. Key points from the call: - Paul Perrault: "I'm pleased to report, we had another quarter of solid earnings... our core loan portfolio grew $82 million or 4.5% annualized and our net interest margin for the second quarter was 3.56%, an increase of seven basis points from the first quarter. We continue to see solid commercial loan and deposit activity in our markets despite the significant rise in short-term rates. I'm pleased with all of the progress the teams at both PCSB Bank and Brookline have been making and continue to expect the transaction to close in the fourth quarter of this year." - Carl Carlson: "Net income this quarter was up $0.5 million from Q1 at $25.2 million, which also included the impact of $535,000 in merger and acquisition costs. Our revenues were up $3.5 million or 5% and expenses excluding merger charges were up 4%. Revenue growth was driven by the growth in interest-earning assets, an increase in our core margin of 11 basis points and solid derivatives and investment volumes. Expense growth was primarily due to compensation associated with annual merit increases, incentive accruals and market adjustments." - On deposits: "During the second quarter, deposits declined $200 million. Tax payments, large real estate purchases and transfers to personal investment accounts drove the decline in deposits." - On interest rates: "We continue to see significant increases in short-term interest rates as the Federal Reserve increased the Fed funds rate 50 basis points in May and another 75 basis points in June. Increases in short-term rates have the potential to benefit us due to our moderately asset-sensitive position. Assuming a flat balance sheet and the forward curve as of June 30, our simulations reflect a 3.1% increase in net interest income over the next 12 months.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.